Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Oral Cavity Cancer Clinical Trials

A listing of Oral Cavity Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (76) clinical trials

Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders

PRIMARY OBJECTIVES: I. To compare standard white light examination to multimodal imaging for detection of high grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially malignant disorders (OPMD). SECONDARY OBJECTIVES: I. To determine qualitative and quantitative diagnostic assessment of patients who agree to undergo imaging and have ...

Phase N/A

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin

PRIMARY OBJECTIVES: I. To determine the safety of radiotherapy (RT) with concurrent and adjuvant anti-PD-L1 therapy (MEDI4736 [durvalumab]) is safe in patients with locoregionally advanced head and neck cancer (HNC) who have a contraindication to cisplatin. (Lead-in) II. To test the hypothesis that concurrent RT and anti-PD-L1 therapy improves progression ...

Phase

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy

PRIMARY OBJECTIVE: To estimate the overall response rate (ORR) of patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) who receive the combination of pembrolizumab and cabozantinib. SECONDARY OBJECTIVES: To estimate the progression-free survival (PFS) of patients treated with the combination of pembrolizumab and cabozantinib. To ...

Phase

TAK228 With Carbo and Taxol in Advanced Malignancies

Study Groups: If participant is found to be eligible to take part in this study, participant will be assigned to a dose level of TAK-228, carboplatin, and paclitaxel based on when participant joins this study. Up to 6 dose levels of TAK-228, carboplatin, and paclitaxel will be tested. Up to ...

Phase

Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue

This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis as a therapeutic modality in a robust scientific randomized prospective clinical trial. Positive outcomes from this study have the potential to dramatically alter the most common morbidity of oral cancer ...

Phase N/A

Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation

The main objective of this trial is to prove the hypothesis that Metformin reduces tissue hypoxia in oral cavity squamous cell carcinoma after a course of treatment of 9-14 days. The primary endpoint of the trial is the change in hypoxia-regulated gene expression upon Treatment with Metformin. Secondary endpoint are ...

Phase N/A

Sentinel. Ambulatory. Oral Cavity. Oropharynx (S.A.C.O)

Currently, patients with oral cancer or oropharynx T1-N0 or T2-N0 are treated by surgery on the tumor and the neck, both validated techniques are either with a systematic lymph node dissection or a search for lymph sentinel node (GS). The goal on the lymph sentinel nodes is to diagnose the ...

Phase N/A

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Study Drug Dose Levels: If you are found to be eligible to take part in this study, you will be assigned to a dose level of Clostridium novyi-NT based on when you join this study. Up to 4 dose levels will be tested. Up to 6 participants will be enrolled ...

Phase

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

This is an open-label, Phase I-II, first-in-human (FIH) study for A166 as monotherapy in HER2-expressing patients who progressed on or did not respond to available standard therapies. Patients enrolled in this Phase III study must have documented HER2 positivity defined as positive on in situ hybridization (ISH) or next-generation sequencing ...

Phase

Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Primary Objectives To determine a safe adjuvant immunotherapy regimen that includes durvalumab with or without tremelimumab to combine with radiotherapy in intermediate-risk HNSCC patients based on dose limiting toxicities. To characterize safety by evaluating Grade 3-5 acute toxicities of adjuvant durvalumab and tremelimumab with radiotherapy in intermediate-risk HNSCC patients. Secondary ...

Phase